Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
Titel:
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer
Auteur:
Kontopodis, E. Kentepozidis, N. Christophyllakis, Ch. Boukovinas, I. Kalykaki, A. Kalbakis, K. Vamvakas, L. Agelaki, S. Kotsakis, A. Vardakis, N. Georgoulias, V. Mavroudis, D.